To keep drug prices high, pharma has been piling up the patents
Add-on patents have increased drug patent periods from two years to over six.
以下正文同步自 Ars Technica，版权归原站所有，已转换为易读排版。
The cost of healthcare in general is a debilitating, pre-existing condition for Americans. But the high prices of prescription drugs usually stand out as a pain point. While there are many insidious reasons why Americans pay more—often far more—for their medicines than people in peer countries, exploitation of the US patent system is an obvious one. A study published Monday in JAMA highlights just how much patent exploitation has grown since 1990. In that time, researchers found the number of patents on small-molecule drugs have more than tripled, going from an average of 2.1 patents per drug approved in 1990 to 6.9 for those approved in 2019. Most of the growth was in "nonprimary" patents—patents that generally aren't related to a drug's active ingredient, but are instead for things like minor tweaks to a drug's non-active ingredients, updates to the way the drug is used, or the design of specialty delivery devices, such as auto-injectors. Together, those extra patents on an individual drug can create what's called a "patent thicket," which delays the release of affordable generics on the market, keeping drug prices higher for longer without actual clinical advancements. Read full article Comments
正文由 探How 从来源站点 RSS 同步，内容未经改写；遇到排版缺失或需要图片、视频时请以原文为准。